NRx Pharmaceuticals (NRXP) news
Recent news
Europe's STOXX 600 pares gains after US CPI, last up 0.46%
European stocks trimmed gains on Thursday as investors digested the latest U.S. inflation data, which showed a 0.4% rise in consumer prices for January, bringing the annual rate to 7.2% . The pan-European STOXX 600 index had earlier risen 0.46% but pared those gains as traders weighed the…
AInvest Wire · 18h agoNrx Pharmaceuticals - FDA reclassifies ANDA amendment for preservative-free ketamine to minor amendment
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has received updated feedback from the U.S. Food and Drug Administration (FDA) regarding its Abbreviated New Drug Application (ANDA) for preservative-free ketamine. The FDA has reclassified a previously identified issue related to the luer lock vial as a…
AInvest Wire · Sep 15, 2026Nrx Pharmaceuticals - FDA revises GDUFA goal date for ANDA amendment to November 10, 2026
The U.S. Food and Drug Administration (FDA) has revised the goal date for the review of Nrx Pharmaceuticals' Abbreviated New Drug Application (ANDA) amendment to November 10, 2026 . This update adjusts the previously established timeline for the agency's evaluation of the amendment, which pertains…
AInvest Wire · Sep 15, 2026NRX Pharmaceuticals - reports cash and cash equivalents of $26.70 mln as of June 30, 2026
AInvest Wire · Aug 17, 2026Nrx Pharmaceuticals - FDA to review certification in shortest possible cycle after Aug 6, 2026 meeting
AInvest Wire · Aug 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.